ATE220333T1 - Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht - Google Patents

Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht

Info

Publication number: ATE220333T1
Authority: AT; Austria
Prior art keywords: active ingredients; salt; angiotensin; insulin sensitivity; pharmaceutical combination
Prior art date: 1996-04-05

Application number

AT97914592T

Other languages

English (en)

Inventor

Norikazu Tamura

Takashi Sohda

Hitoshi Ikeda

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-05

Filing date

1997-04-03

Publication date

2002-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=13815962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE220333(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-03 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2002-07-15 Application granted granted Critical

2002-07-15 Publication of ATE220333T1 publication Critical patent/ATE220333T1/de

Links

239000004480 active ingredient Substances 0.000 title 2
102000005862 Angiotensin II Human genes 0.000 title 1
101800000733 Angiotensin-2 Proteins 0.000 title 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title 1
206010022489 Insulin Resistance Diseases 0.000 title 1
229950006323 angiotensin ii Drugs 0.000 title 1
230000003042 antagnostic effect Effects 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
229960002632 acarbose Drugs 0.000 abstract 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 abstract 1
HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

AT97914592T 1996-04-05 1997-04-03 Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht ATE220333T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP8391796		1996-04-05
PCT/JP1997/001149 WO1997037688A2 (en)	1996-04-05	1997-04-03	Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity

Publications (1)

Publication Number	Publication Date
ATE220333T1 true ATE220333T1 (de)	2002-07-15

Family

ID=13815962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97914592T ATE220333T1 (de)	1996-04-05	1997-04-03	Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht

Country Status (22)

Country	Link
US (2)	US6107323A (de)
EP (4)	EP1192951A3 (de)
JP (2)	JPH09323940A (de)
KR (2)	KR19990087076A (de)
CN (1)	CN1215338A (de)
AT (1)	ATE220333T1 (de)
AU (1)	AU713277B2 (de)
BR (1)	BR9708517A (de)
CA (3)	CA2650637A1 (de)
CY (1)	CY2300B1 (de)
CZ (1)	CZ297941B6 (de)
DE (1)	DE69713890T3 (de)
DK (1)	DK0914158T4 (de)
ES (1)	ES2175385T5 (de)
NO (1)	NO321388B1 (de)
NZ (1)	NZ330774A (de)
PL (2)	PL189066B1 (de)
PT (1)	PT914158E (de)
RU (1)	RU2188013C2 (de)
SI (1)	SI0914158T2 (de)
SK (1)	SK283348B6 (de)
WO (1)	WO1997037688A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6268392B1 (en) *	1994-09-13	2001-07-31	G. D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
CA2224451A1 (en) *	1995-06-30	1997-01-23	Merck & Co., Inc.	Method of treating renal disease using an ace inhibitor and an aii antagonist
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
US6107323A (en) *	1996-04-05	2000-08-22	Takeda Chemical Industries, Ltd.	Pharmaceutical composition
JP2008094852A (ja) *	1996-07-15	2008-04-24	Daiichi Sankyo Co Ltd	医薬
AU714618B2 (en)	1996-07-15	2000-01-06	Sankyo Company Limited	Medicinal composition
EP1007038A2 (de) *	1997-08-21	2000-06-14	Takeda Chemical Industries, Ltd.	Entzündungshemmendes mittel
US7105552B2 (en) *	1998-05-08	2006-09-12	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
AU779354B2 (en)	1998-12-23	2005-01-20	Orphan Medical, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6756360B1 (en)	1998-12-24	2004-06-29	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
WO2000043007A1 (en) *	1999-01-19	2000-07-27	Sankyo Company, Limited	Troglitazone-containing medicinal compositions for inhibiting apoptosis
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
US7407978B2 (en) *	1999-04-06	2008-08-05	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
WO2000066161A1 (en)	1999-04-28	2000-11-09	Takeda Chemical Industries, Ltd.	Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
EP1197226B1 (de) *	1999-07-21	2007-11-21	Takeda Pharmaceutical Company Limited	Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens
JP4000505B2 (ja)	1999-12-01	2007-10-31	第一三共株式会社	緑内障を治療するための併用剤
PL356422A1 (en) *	2000-02-18	2004-06-28	Takeda Chemical Industries, Ltd.	Tnf-alpha inhibitors
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
AU2001284413A1 (en) *	2000-08-30	2002-03-13	Sankyo Company Limited	Medicinal compositions for preventing or treating heart failure
US20020173535A1 (en) *	2001-02-07	2002-11-21	Renshaw Perry F.	Cholesterol-lowering agents as treatment for psychological and cognitive disorders
US20030078190A1 (en) *	2001-05-25	2003-04-24	Weinberg Marc S.	Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
GB0113570D0 (en)	2001-06-04	2001-07-25	Hewlett Packard Co	Audio-form presentation of text messages
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
AU2002349673A1 (en) *	2001-12-03	2003-06-17	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents
JP4484427B2 (ja) *	2001-12-03	2010-06-16	武田薬品工業株式会社	インスリン抵抗性改善剤
MY131170A (en)	2002-03-28	2007-07-31	Nissan Chemical Ind Ltd	Therapeutic agent for glomerular disease
US20030229007A1 (en) *	2002-05-30	2003-12-11	Roberto Levi	Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2006500378A (ja) *	2002-08-21	2006-01-05	メルク　エンド　カムパニー　インコーポレーテッド	二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
ATE551056T1 (de) *	2002-12-27	2012-04-15	Takeda Pharmaceutical	Mittel zur hemmung der körpergewichtszunahme
DE10301371A1 (de) *	2003-01-16	2004-08-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20050004193A1 (en) *	2003-01-16	2005-01-06	Boehringer Ingelheim International Gmbh	Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
JPWO2005011736A1 (ja) *	2003-07-30	2006-09-14	株式会社東北テクノアーチ	アルツハイマー病の予防および／または治療剤
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
US20050250734A1 (en) *	2003-11-07	2005-11-10	The Procter & Gamble Company	Compositions, kits, and methods for the treatment of conditions associated with elevated cholesterol levels
WO2005070398A2 (en) *	2004-01-23	2005-08-04	Ranbaxy Laboratories Limited	Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
US20060039890A1 (en) *	2004-08-20	2006-02-23	Renshaw Perry F	Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
UY29155A1 (es) *	2004-10-07	2006-02-24	Takeda Pharmaceutical	Un agente para la profilaxis o tratamietno del sindrome metabolico
WO2006079496A1 (en) *	2005-01-26	2006-08-03	Lek Pharmaceuticals D.D.	New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ562887A (en) *	2005-03-30	2010-10-29	Takeda Pharmaceutical	Benzimidazole derivative and use as angiotensin II antagonist
US8242151B2 (en)	2007-02-07	2012-08-14	Kyowa Hakko Kirin Co., Ltd.	Tricyclic compounds
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
AR065850A1 (es) *	2007-03-28	2009-07-08	Takeda Pharmaceutical	Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
US20090074831A1 (en) *	2007-09-18	2009-03-19	Robert Falotico	LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2009088006A1 (ja) *	2008-01-10	2009-07-16	Daiichi Sankyo Company, Limited	併用医薬
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
US20110117194A1 (en)	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
BRPI0912014A2 (pt)	2008-05-09	2019-03-06	Grünenthal GmbH	processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
RU2015138422A (ru)	2009-07-22	2018-12-25	Грюненталь Гмбх	Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh)	2009-07-22	2012-07-11	格吕伦塔尔有限公司	热熔挤出的控制释放剂型
NZ607392A (en)	2010-09-02	2015-03-27	Gruenenthal Chemie	Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo um polímero aniônico.
RS56527B1 (sr)	2011-07-29	2018-02-28	Gruenenthal Gmbh	Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es)	2011-07-29	2014-11-22	Gruenenthal Chemie	Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en)	2012-04-18	2018-11-19	Gruenenthal Gmbh	MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6224586B2 (ja) *	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
AR096439A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en)	2013-11-26	2020-05-28	Grunenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es)	2014-05-12	2017-03-06	Gruenenthal Gmbh	Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es)	2014-05-26	2017-02-22	Gruenenthal Gmbh	Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en)	2015-09-10	2018-02-22	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0238580B2 (ja) *	1981-06-02	1990-08-31	Takeda Chemical Industries Ltd	Bariooruaminnonnchikanjudotai*sonoseizohooyobyoto
EP0400835A1 (de) *	1989-05-15	1990-12-05	Merck & Co. Inc.	Substituierte Benzimidazole als Angiotensin II-Hemmer
DK0514452T4 (da) *	1990-02-09	2000-09-18	Upjohn Co	Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU2147875C1 (ru) *	1990-05-11	2000-04-27	Пфайзер Инк.	Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
CA2040865C (en) *	1990-05-15	2002-07-23	James L. Bergey	Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) *	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
AU656551B2 (en) *	1990-12-14	1995-02-09	Smithkline Beecham Corporation	Angiotensin II receptor blocking compositions
AU1256692A (en) *	1991-02-06	1992-09-07	Schering Corporation	Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
EP0503838A3 (en) *	1991-03-08	1992-10-07	Merck & Co. Inc.	Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
US5162340A (en) *	1991-05-10	1992-11-10	Merck & Co., Inc.	Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
HU217629B (hu) *	1991-12-12	2000-03-28	Novartis Ag.	Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
EP0636027B1 (de) *	1992-04-13	1999-07-07	Zeneca Limited	ANGIOTENSIN-II-ANTAGONISTEN GEGEN ERKRANKUNGEN; DIE MIT EINER EINGESCHRäNKTEN; NEURONALEN LEITUNGSGESCHWINDIGKEIT VERBUNDEN SIND, INSBESONDERE DIABETISCHE NEUROPATHIE
US5266583A (en) *	1992-09-01	1993-11-30	Merck & Co., Inc.	Angitotensin II antagonist
DE4315349A1 (de) *	1992-10-06	1994-11-10	Thomae Gmbh Dr K	Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5300668A (en) *	1993-03-10	1994-04-05	Pfizer Inc.	Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates
CA2125251C (en) *	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (ja) *	1993-06-07	2000-06-26	武田薬品工業株式会社	アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
EP0629408A1 (de) *	1993-06-16	1994-12-21	LABORATOIRES MERCK, SHARP & DOHME-CHIBRET	Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
EP0635263A3 (de) *	1993-06-28	1995-09-27	American Cyanamid Co	Angiotensin (AII)-antagonisten als Inhibitoren des Wachstums von Fettgewebe.
JP3883205B2 (ja) *	1994-03-29	2007-02-21	メルクエンドカンパニーインコーポレーテッド	アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
GB9406573D0 (en) *	1994-03-31	1994-05-25	Merck Sharp & Dohme	Medicaments
FR2733911B1 (fr) *	1995-05-09	1998-05-29	Takeda Chemical Industries Ltd	Composition pharmaceutique pour maladies renales ou cardio-vasculaires
FR2735365B1 (fr) *	1995-06-14	1997-09-05	Sanofi Sa	Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2224451A1 (en) *	1995-06-30	1997-01-23	Merck & Co., Inc.	Method of treating renal disease using an ace inhibitor and an aii antagonist
US5798375A (en) *	1995-07-03	1998-08-25	Sankyo Company, Limited	Treatment of arteriosclerosis and xanthoma
US6107323A (en) *	1996-04-05	2000-08-22	Takeda Chemical Industries, Ltd.	Pharmaceutical composition

1997
- 1997-04-03 US US08/836,784 patent/US6107323A/en not_active Expired - Lifetime
- 1997-04-03 RU RU98119885/14A patent/RU2188013C2/ru not_active IP Right Cessation
- 1997-04-03 CA CA002650637A patent/CA2650637A1/en not_active Abandoned
- 1997-04-03 EP EP01124024A patent/EP1192951A3/de not_active Withdrawn
- 1997-04-03 ES ES97914592T patent/ES2175385T5/es not_active Expired - Lifetime
- 1997-04-03 EP EP07009568A patent/EP1813286A3/de not_active Withdrawn
- 1997-04-03 AT AT97914592T patent/ATE220333T1/de active
- 1997-04-03 WO PCT/JP1997/001149 patent/WO1997037688A2/en not_active Ceased
- 1997-04-03 PL PL97329188A patent/PL189066B1/pl not_active IP Right Cessation
- 1997-04-03 CZ CZ0288698A patent/CZ297941B6/cs not_active IP Right Cessation
- 1997-04-03 NZ NZ330774A patent/NZ330774A/xx not_active IP Right Cessation
- 1997-04-03 CA CA002241466A patent/CA2241466C/en not_active Expired - Fee Related
- 1997-04-03 BR BR9708517A patent/BR9708517A/pt not_active IP Right Cessation
- 1997-04-03 KR KR1019980706462A patent/KR19990087076A/ko not_active Ceased
- 1997-04-03 AU AU21780/97A patent/AU713277B2/en not_active Ceased
- 1997-04-03 SK SK1278-98A patent/SK283348B6/sk not_active IP Right Cessation
- 1997-04-03 DK DK97914592T patent/DK0914158T4/da active
- 1997-04-03 KR KR1020057007489A patent/KR20050047560A/ko not_active Ceased
- 1997-04-03 DE DE69713890T patent/DE69713890T3/de not_active Expired - Lifetime
- 1997-04-03 CN CN97193515A patent/CN1215338A/zh active Pending
- 1997-04-03 EP EP10173392A patent/EP2253327A1/de not_active Withdrawn
- 1997-04-03 PL PL367915A patent/PL193365B1/pl not_active IP Right Cessation
- 1997-04-03 PT PT97914592T patent/PT914158E/pt unknown
- 1997-04-03 EP EP97914592A patent/EP0914158B2/de not_active Expired - Lifetime
- 1997-04-03 CA CA002577233A patent/CA2577233C/en not_active Expired - Fee Related
- 1997-04-03 SI SI9730391T patent/SI0914158T2/sl unknown
- 1997-04-04 JP JP9086484A patent/JPH09323940A/ja active Pending
1998
- 1998-09-07 NO NO19984123A patent/NO321388B1/no not_active IP Right Cessation
2000
- 2000-04-18 US US09/551,546 patent/US6432996B1/en not_active Expired - Fee Related
2002
- 2002-10-22 CY CY0200060A patent/CY2300B1/xx unknown
2008
- 2008-04-21 JP JP2008110085A patent/JP2008195736A/ja active Pending

Also Published As

Publication number	Publication date
CA2577233C (en)	2009-08-18
SI0914158T2 (sl)	2006-04-30
CY2300B1 (en)	2003-07-04
CN1215338A (zh)	1999-04-28
CZ288698A3 (cs)	1998-12-16
NO984123L (no)	1998-09-07
NZ330774A (en)	1999-06-29
ES2175385T5 (es)	2006-06-01
WO1997037688A2 (en)	1997-10-16
DE69713890D1 (de)	2002-08-14
DK0914158T3 (da)	2002-10-14
DK0914158T4 (da)	2006-03-06
CA2241466C (en)	2007-05-22
CZ297941B6 (cs)	2007-05-02
US6107323A (en)	2000-08-22
PL193365B1 (pl)	2007-02-28
DE69713890T2 (de)	2002-11-21
SI0914158T1 (en)	2002-12-31
CA2650637A1 (en)	1997-10-16
AU2178097A (en)	1997-10-29
EP1813286A3 (de)	2008-04-16
EP0914158B1 (de)	2002-07-10
EP1192951A2 (de)	2002-04-03
CA2577233A1 (en)	1997-10-16
JP2008195736A (ja)	2008-08-28
PL189066B1 (pl)	2005-06-30
KR19990087076A (ko)	1999-12-15
AU713277B2 (en)	1999-11-25
EP0914158A2 (de)	1999-05-12
BR9708517A (pt)	1999-08-03
EP1813286A2 (de)	2007-08-01
SK127898A3 (en)	1999-05-07
DE69713890T3 (de)	2006-09-07
SK283348B6 (sk)	2003-06-03
WO1997037688A3 (en)	1998-03-05
PT914158E (pt)	2002-11-29
ES2175385T3 (es)	2002-11-16
NO984123D0 (no)	1998-09-07
EP1192951A3 (de)	2004-04-21
US6432996B1 (en)	2002-08-13
NO321388B1 (no)	2006-05-02
KR20050047560A (ko)	2005-05-20
JPH09323940A (ja)	1997-12-16
EP0914158B2 (de)	2006-01-25
RU2188013C2 (ru)	2002-08-27
PL329188A1 (en)	1999-03-15
EP2253327A1 (de)	2010-11-24
CA2241466A1 (en)	1997-10-16

Legal Events

Date

Code

Title

Description

2002-10-15

UEP

Publication of translation of european patent specification

2006-12-15

UEP